Health Care & Hospital Law,
Civil Litigation,
Antitrust & Trade Reg.
Apr. 8, 2022
Aetna, Gilead argue over US or state venue for antitrust claims
U.S. District Judge Edward M. Chen said there were two important questions to answer: whether there ought to be an estoppel against Aetna for seeking remand, and if an implicit federal jurisdiction question exists in the state cause of action.
Aetna Inc. and Gilead Sciences Inc. faced off Thursday over whether Aetna’s antitrust claims against Gilead were more suited for federal or state court where the case was originally filed.
U.S. District Judge Edward M. Chen said there were two important questions to answer: whether there ought to be an estoppel against Aetna for seeking remand, and if an implicit federal jurisdiction question exists in the state cause of action.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In